Forecast to Publish a Notice of Funding Opportunity for SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)
Last verified by NonDilute: 2026-06-08. Official notice and agency instructions control.
If you have an NIH Phase II SBIR win in cancer tech and are ready to de-risk a path to market or trials, this bridge award could fund the critical next step.
Report stale or inaccurate summary
What this is
The NIH is forecasting a Phase IIB Bridge funding opportunity (R44 mechanism) to accelerate cancer-focused technology development by small businesses. Phase IIB bridges typically support companies that have completed Phase II validation and are preparing for Phase III trials or market entry. The optional clinical trial language suggests applicants may incorporate human studies. This is a follow-on award for companies with prior SBIR Phase I or II success in oncology-relevant areas.
Who can apply
Eligible applicants are small businesses (unspecified size caps apply by SBIR rules, typically 500 employees). Applicants must have completed or be completing an NIH SBIR Phase I or II project. U.S.-based companies only. Specific eligibility details are not yet published; consult the Notice of Funding Opportunity when released.
Topics: sbir phase iib · cancer technology · clinical trial optional · commercialization · nih bridge award · oncology development
Public-source funding discovery only. This summary is generated from public agency data and may be incomplete or stale. NonDilute is not affiliated with, endorsed by, or acting on behalf of any government agency. Official notices and agency instructions control. NonDilute does not determine eligibility, provide grant-writing advice, or guarantee funding.